Adrenomedullin for Risk Stratification of Emergency Patients With Nonspecific Complaints: An Interventional Multicenter Pilot Study

What Was Tested

Researchers studied Adrenomedullin in this randomized controlled trial publication.

Patients with nonspecific complaints (NSC) presenting to the emergency department (ED) are at risk of life-threatening conditions.

New stress biomarkers such as the midregional portion of adrenomedullin (MR-proADM) promise to support decision-making.

Who Took Part

The study group was 398 patients.

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.

Regarding disposition, patients were assigned to 1 of 3 risk classes: high-risk (admission to hospital), intermediate risk (community geriatric hospital), and low-risk patients (discharge).

How the Study Was Run

The design is described as randomized, multicenter and pilot.

The patients were allocated by chance, so the Adrenomedullin group and the comparison group should start out alike.

More than one site took part, so the patients came from several places.

It is described as a pilot, a small early test of whether a larger Adrenomedullin study would be practical.

What Was Measured

Patients were randomly assigned to either the standard group (decision-making solely based on clinical assessment) or the Novum group (biomarker-assisted).

In the Novum group, in addition to clinical risk assessment, the information of the MR-proADM level was used.

Topics PubMed links to this paper include Adrenomedullin, Algorithms, Biomarkers, Decision Making, Emergency Service, Hospital, Pilot Projects and Risk Assessment.

What This Means in Plain Language

The paper is a randomized, multicenter and pilot study of Adrenomedullin in 398 patients.

With several hundred people or more, it is a fairly large study for this kind of research.

The publication is from 2016 (Medicine), a journal based in United States.

More context: the Adrenomedullin compound page, all human trials.